However, peptides are readily broken down during digestion which is why Ozempic (approved for diabetes) and Wegovy (just a higher dose of semaglutide approved for weight loss) have to be injected
and (iii) activation of the glyoxylate shunt (isocitrate lyase BC1128* , malate synthase BC1127* ), a bypass of the TCA which converts isocitrate to glyoxylate to malate
Both formulations contain identical semaglutide molecules
This article outlines the expected timeline, the factors that influence individual response, and what the current clinical evidence shows
[4] Wegovy is administered as a once-weekly subcutaneous injection, with dosing gradually increased over 16-20 weeks (starting at 0.25 mg and increasing monthly to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg) to minimise gastrointestinal side effects